The 2023 WHO updates on skin tumors: advances since the 2018 edition.

WHO classification histology immunohistochemistry molecular pathology skin tumors

Journal

Pathologica
ISSN: 1591-951X
Titre abrégé: Pathologica
Pays: Italy
ID NLM: 0401123

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 07 04 2024
accepted: 12 04 2024
medline: 8 10 2024
pubmed: 8 10 2024
entrez: 8 10 2024
Statut: ppublish

Résumé

Pathology is pivotal in diagnosing skin tumors, and the precision of diagnosis is crucial to devise customized treatment plans and enhance patient care in dermatology. The latest edition of the World Health Organization's classification of skin tumors serves as a comprehensive compendium, summarizing and categorizing all recent advancements in both anatomical-pathological and molecular aspects of cutaneous neoplasms. Several relevant advances have been introduced and new entities have been described. While the fundamental structure of the classification remains unchanged, notable additions include three new sections aimed at providing a more exhaustive description of skin lesions: nail unit tumors, skin metastases, and genetic tumor syndromes associated with skin malignancies. Recent strides in molecular pathology have led to significant breakthroughs in decoding the underlying mechanisms of various skin tumors, ranging from adnexal neoplasms to hematolymphoid neoplasms, soft tissue tumors, and melanocytic lesions. Of particular importance is the evolution in our understanding of melanocytic neoplasms, with the introduction of the term "melanocytoma" reserved for lesions exhibiting "intermediate" biological behavior and characterized by specific molecular mutations. The pathologic diagnosis process integrates morphological, immunohistochemical, and molecular features, playing a crucial role in clinical decision-making. The WHO classification serves as a valuable tool in promoting multidisciplinarity in the management of cutaneous neoplasms with the aim of translating novel pathological discoveries into more effective treatments. This review aims to distill the major updates introduced by the new classification, providing a synthesis of the latest scientific insights.

Identifiants

pubmed: 39377501
doi: 10.32074/1591-951X-1006
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

193-206

Informations de copyright

Copyright © 2024 Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology.

Auteurs

Francesco Fortarezza (F)

University Hospital of Padova, Surgical Pathology and Cytopathology Unit, Padova, Italy.

Gerardo Cazzato (G)

Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), Pathology Unit, University of Bari "Aldo Moro", Bari, Italy.

Giuseppe Ingravallo (G)

Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), Pathology Unit, University of Bari "Aldo Moro", Bari, Italy.

Angelo Paolo Dei Tos (AP)

University Hospital of Padova, Surgical Pathology and Cytopathology Unit, Padova, Italy.
Department of Medicine-DIMED, University of Padova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH